Amicus Therapeutics, Inc.  

(Public, NASDAQ:FOLD)   Watch this stock  
Find more results for FOLD
8.20
-0.06 (-0.73%)
Real-time:   2:08PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.03 - 8.27
52 week 1.76 - 9.63
Open 8.12
Vol / Avg. 457,093.00/1.78M
Mkt cap 800.03M
P/E     -
Div/yield     -
EPS -0.90
Shares 95.56M
Beta 1.70
Inst. own 54%
Mar 2, 2015
Q4 2014 Amicus Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 13, 2015
Amicus Therapeutics Inc at JPMorgan Healthcare Conference
Dec 11, 2014
Amicus Therapeutics Inc at Oppenheimer Healthcare Conference
Nov 6, 2014
Q3 2014 Amicus Therapeutics Inc Earnings Call
Nov 6, 2014
Q3 2014 Amicus Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -5852.90% -16427.82%
Operating margin -5739.25% -17680.72%
EBITD margin - -16521.76%
Return on average assets -56.50% -50.19%
Return on average equity -172.86% -103.74%
Employees 92 -
CDP Score - -

Address

1 Cedar Brook Drive
CRANBURY, NJ 08512
United States - Map
+1-609-6622000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amicus Therapeutics, Inc., is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders. The Company�s development programs include next-generation enzyme replacement therapies for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharoidosis Type I. The Company is also developing small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Patients with LSDs who are receiving ERT, the infused exogenous protein may unfold and lose activity at any stage in the process from the infusion bag to the bloodstream, to the eventual uptake into cells and tissue. The Company�s Chaperone-Advanced Replacement Therapy, or CHART, platform has been used to develop its next-generation ERTs by co-formulating therapeutic enzymes with its pharmacological chaperones.

Officers and directors

John F. Crowley J.D. Chairman of the Board, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Bradley L. Campbell President, Chief Operating Officer
Age: 39
Bio & Compensation  - Reuters
William D. Baird III Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Hung Do Ph.D. Senior Vice President - Discovery Biology
Age: 46
Bio & Compensation  - Reuters
Dipal Doshi Senior Vice President - Business Planning and Development
Bio & Compensation  - Reuters
Ken Valenzano Ph.D. Senior Vice President - Preclinical Research
Age: 46
Bio & Compensation  - Reuters
Enrique Dilone Ph.D. Vice President - Technical Operations
Age: 47
Bio & Compensation  - Reuters
Daphne E. Quimi Vice President - Finance, Controller
Age: 48
Bio & Compensation  - Reuters
Jeffrey P. Castelli Ph.D. Vice President - Program and Portfolio Management
Age: 42
Bio & Compensation  - Reuters
Jayne Gershkowitz Vice President - Patient Advocacy & Public Policy
Age: 57
Bio & Compensation  - Reuters